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Introduction
Regeneration of BH4 from quinonoid dihydrobiopterin (qBH2) derivative is catalyzed by dihydropteridine reductase (DHPR). DHPR is the enzyme ne cessary for recycling of the cofacter BH 4 . Some DHPR deficiency patients have been described who did not respond to higher dose of BH4(l).
DHPR deficiency is a rare disorder during childhood. We present a boy with hyperphenylalaninemia due to DHPR deficiency.
Materials and Methods
The subject was a male, born at 38 weeks of gestation, weighing 3.1 kg. He was the second child of nonconsaguineous patients. The patient was diagnosed with hyperbilirubinemia. On a routine Guthrie test for neonatal screening, his serum phenylalanine level ranged between 8.2 and 12.6 mg/dl.
At the age of 30 day, BH4 (Sapropterin hydrochloride : Biopterin, Suntory K .K ) was administered orally at the dose of 10 mg/kg. Blood samples were taken immediately before and 2, 4 , 8 and 24 h after administration.
Results
The patient did not respond to a load dose of 10 mg/kg BH4 (Table 1) . In the patient the neopterin (N) is very high , however, biopterin (B) is also high and thus the neopteriJ.1lbiopterin ratio increased. The DHPR activity in dried blood spots on filter paper was 0 nmol/minlSrnmdisc (Table 3 ) (2). The patient did not respond to BH4 loading at doses of 20 and 30 mg/kg. At the age of 8 weeks, he was introduced to daily BH4 therapy (30 mg/kg in three doses) without Phe-restricted formula, consequently his serum phenylalanine levels decreased from 25.6 mg/dl to 1.1 (Figure 1) . He was administered with a daily dosage of 10-15 mg/kg of BH 4 . After BH4 therapy was initiated, his CSF concentrations of HVA and 5HlAA did not increase (Table 4) ..,., 
Discussion
DHPR deficiency blocks the normal recycling of qBH 2 . Some DHPR deficient patients could be misdiagnosed, because their serum Phe levels were not lowered after the BH4 loading (1). In DHPR deficiency, most subjects show a fall in Phe and a rise in Tyr levels with large enough doses ofBH 4 . The patient in this study failed to respond to bolus 30 mg/kg ofBH 4 10ad-Lng, but was able to daily 30 mg/kg of BH4 without Phe-restricted formula . In our case, he required a daily dosage of 15 mg/kg BH4 to keep his serum Phe concentrations (2-8mg/dl) under control.
If exogenous BH4 can be used in DHPR deficiency to convert Phe to Tyr, it is likely that it will be involved in the Tyr and Trp hydroxylation reactions in the brain. After BH4 therapy (daily 30mg/kg) was initiated, his CSF concentrations of HVA and 5HIAA did not increase. BH4 therapy might be ineffective in restoring sufficient dopamine and serotonin production at the central level due to the poor brain entry of synthetic cofactor. With severely defective amine synthesis, administraion of L-dopa and a decarboxylase inhibitor (carbidopa) in a ratio of 1: 10 (Neodopaston), combined with 5-HTP at doses I O-12mgl kg/d L-dopa and I 0-12mg.lkg/d of 5-HTP, will restore CSF amine metabolic concentrations to the normal range and control symptoms. It is important to measure CSF amine metabolites at intervals. Serum prolactin is known to be an excellent marker of the hypothalamic dopamine content (3) . Serum prolactin profiles may correspond with measurements of catecholamine metabolites in CSF for the evaluation of therapeutic L-DOPA/carbidopa adjustments in severe BH4 deficiency. Serum prolactin measurements can be performed both frequently and easily by routine blood sampling, avoiding the painful way of lumbar puncture. SeIUm prolactin profiles provide information on the brain catecholamine states and may serve as a potentially useful and easy tool in estimating the catecholamine content in the CSF of DHPR deficiency patient.
